8-K: BioAtla Reports Positive Clinical Trial Updates and Secures Funding Runway into 2026

BioAtla announced encouraging clinical trial results for its cancer therapies and a license agreement that extends its cash runway into early 2026.

Summary

• BioAtla released its third quarter 2024 financial results and provided updates on its clinical programs.
• The company's ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial for squamous cell carcinoma of the head and neck (SCCHN) showed a median overall survival of approximately 9 months in a heavily pretreated population.
• Evalstotug (CAB-CTLA-4) in combination with PD-1 demonstrated tumor reduction in all eight first-line unresectable or metastatic melanoma patients, including a complete response in one patient.
• Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 trial in non-small cell lung cancer (NSCLC) showed an improved median overall survival of 12.6 months among patients with tumors expressing mutant KRAS variants.
• BioAtla entered into a worldwide license agreement for a preclinical CAB-Nectin-4 bispecific T-cell engager, which will provide up to $133.5 million in aggregate payments.
• The company's cash balance is projected to fund operations into early 2026.
• Research and development expenses decreased to $16.4 million for the quarter ended September 30, 2024, compared to $28.4 million for the same quarter in 2023.
• Net loss for the quarter ended September 30, 2024, was $10.6 million, including $11.0 million in collaboration revenue, compared to a net loss of $33.3 million for the same quarter in 2023.
• Cash and cash equivalents as of September 30, 2024, were $56.5 million, compared to $111.5 million as of December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical trial results, a significant licensing agreement, and an extended cash runway. The decrease in net loss and R&D expenses further contribute to the positive sentiment. However, the decrease in cash balance and reliance on strategic partnerships temper the overall optimism.

Positives

• The ozuriftamab vedotin trial showed promising median overall survival of approximately 9 months in a difficult to treat patient population.
• Evalstotug demonstrated strong anti-tumor activity with a 100% tumor reduction rate in the first-line melanoma patients, including a complete response.
• Mecbotamab vedotin showed an improved median overall survival of 12.6 months in NSCLC patients with mutant KRAS variants compared to 8.7 months for wildtype.
• The license agreement for the CAB-Nectin-4 bispecific T-cell engager provides significant revenue and validation of the technology.
• The company has extended its cash runway into early 2026, providing financial stability.
• The company has received actionable feedback from the FDA regarding pivotal trials for ozuriftamab vedotin and evalstotug.
• The company is well-positioned for two potentially registrational trials in 2025.

Negatives

• The company's cash balance decreased from $111.5 million at the end of 2023 to $56.5 million as of September 30, 2024.
• The company is still experiencing a net loss, although it has decreased significantly compared to the same quarter last year.
• The company is reliant on strategic partnerships to further develop its Phase 2 clinical assets.

Risks

• Clinical trials may experience delays or fail to meet anticipated endpoints.
• Regulatory approvals are not guaranteed and may be delayed.
• The company is dependent on the success of its CAB technology platform.
• The company relies on third parties for manufacturing, supply, and clinical trial conduct.
• The company may face challenges in enrolling patients in clinical trials.
• The company may not be able to form collaborations or partnerships with third parties.
• The company is subject to risks associated with COVID-19 and its variants.

Future Outlook

BioAtla expects its current cash and cash equivalents to fund operations into early 2026 and anticipates initiating two potentially registrational trials in 2025. The company also expects to establish a near-term collaboration for one of its Phase 2 clinical assets.

Management Comments

• Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc., stated that the company is seeing encouraging overall survival data in both of its ADC programs and promising antitumor activity and tolerability with its CAB-CTLA4 antibody, evalstotug.
• Management believes the company is well-positioned for two potentially registrational trials in 2025 following positive interactions with the FDA.
• Management remains confident in establishing a near-term collaboration for one of its Phase 2 clinical assets.

Industry Context

The announcement reflects the ongoing trend in the biotechnology industry towards developing targeted therapies, such as antibody-drug conjugates and bispecific antibodies, for cancer treatment. The focus on conditionally active biologics (CABs) aligns with the industry's efforts to improve efficacy and reduce toxicity of cancer treatments. The company's progress in multiple cancer types and its strategic partnership approach are consistent with industry best practices.

Comparison to Industry Standards

• The median overall survival of approximately 9 months for ozuriftamab vedotin in heavily pretreated SCCHN patients is comparable to or better than some other treatments in this difficult-to-treat population, but direct comparisons are difficult without specific trial details of other treatments.
• The 100% tumor reduction rate with evalstotug in first-line melanoma patients, including a complete response, is a very promising result and appears to be at the higher end of the efficacy spectrum compared to other CTLA-4 inhibitors, though further data is needed to confirm this.
• The 12.6-month median overall survival for mecbotamab vedotin in mKRAS NSCLC patients is competitive with other targeted therapies in this space, but direct comparisons are difficult without specific trial details of other treatments.
• The licensing agreement with Context Therapeutics for the CAB-Nectin-4 bispecific T-cell engager is a positive sign of the value of BioAtla's technology and is similar to other strategic partnerships in the biotech industry.

Stakeholder Impact

• Shareholders will likely view the clinical trial results and extended cash runway positively.
• Employees may feel more secure with the company's financial stability.
• Patients may benefit from the development of new cancer therapies.
• Potential partners may be more interested in collaborating with BioAtla due to the positive clinical data and financial outlook.

Next Steps

• BioAtla will continue dose optimization for CAB-ROR2 and CAB-CTLA4.
• The company plans to position these two programs for potentially registrational trials.
• BioAtla will continue to seek a strategic collaboration for at least one of its Phase 2 assets.
• The company anticipates a data readout of the Phase 1 study for BA3182 around mid-2025.

Key Dates

Keywords

BioAtla, CAB technology, Ozuriftamab vedotin, Evalstotug, Mecbotamab vedotin, Antibody-drug conjugate, Cancer therapy, Clinical trials, Immunotherapy, SCCHN, Melanoma, NSCLC, T-cell engager, FDA, Biotechnology